Fracture Prevention with Zoledronate in Older Women with Osteopenia

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

2000 postmenopausal women with osteopenia were randomized to treatment with infusion of either zoledronate 5mg or placebo every 18 months for 6 years. Participants were assessed for incidence of fractures, prespecified adverse events including mortality, vascular events, cancer, and osteonecrosis of the jaw, and bone mineral density after 6 years. Results demonstrated significantly lower incidences of fragility fractures, including vertebral and nonvertebral fractures, among women administered zoledronate 5mg in comparison to placebo. No significant differences in the rates of adverse events were noted between groups, with the exception of a lower rate of cancer among the zoledronate group compared to placebo group. No participant in either group demonstrated atypical femoral fracture or osteonecrosis of the jaw. Bone mineral density measures at the lumbar spine, total hip, and total body demonstrated increases from baseline after 6 years in the zoledronate group, in contrast to decreases from baseline after 6 years in the placebo group.